NCT02031224

Brief Summary

This is a prospective single center randomized controlled trial with a total duration of 18 months aiming to evaluate the effectiveness and the safety of a very low protein diet supplemented with ketoanalogues of essential aminoacids in reducing the progression of chronic kidney disease (CKD) in patients with advanced CKD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Mar 2008

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2008

Completed
5.9 years until next milestone

First Submitted

Initial submission to the registry

January 7, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 9, 2014

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2014

Completed
Last Updated

December 22, 2017

Status Verified

December 1, 2017

Enrollment Period

6.3 years

First QC Date

January 7, 2014

Last Update Submit

December 21, 2017

Conditions

Keywords

Chronic Kidney DiseaseRestricted protein dietsNutritional status

Outcome Measures

Primary Outcomes (1)

  • Primary composite endpoint

    Need for renal replacement therapy or an at least 50% reduction in the estimated glomerular filtration rate compared to randomization

    15 months after randomization

Secondary Outcomes (16)

  • Secondary efficacy parameter

    months 3-15 after randomization

  • Secondary outcome measure - nitrogen balance

    15 months after randomization

  • Secondary efficacy parameter - mineral metabolism

    15 weeks after randomization

  • Secondary efficacy parameter

    15 weeks after randomization

  • Secondary efficacy parameter

    15 weeks after randomization

  • +11 more secondary outcomes

Other Outcomes (2)

  • Compliance - protein intake

    18 months after enrolment

  • Compliance - energy intake

    18 weeks after enrolment

Study Arms (2)

Keto-diet (KD)

EXPERIMENTAL

Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.

Dietary Supplement: Very low protein diet supplemented with Ketosteril

Low Protein Diet group (LPD)

ACTIVE COMPARATOR

The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins). The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms.

Behavioral: Conventional low protein diet

Interventions

Also known as: LPD, Hypoproteic diet
Low Protein Diet group (LPD)
Also known as: SVLPD, Keto-diet
Keto-diet (KD)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult non-diabetic patients
  • stage 4-5 CKD not on dialysis (estimated glomerular filtration by Modification of Diet in Renal Disease formula \< 30 mL/min per year
  • stable renal function at least 12 weeks before enrollment
  • well-controlled arterial blood pressure
  • proteinuria less than 1 g/g urinary creatinine
  • good nutritional status
  • declared and anticipated good compliance with the prescribed diet

You may not qualify if:

  • poorly controlled arterial blood pressure (≥145/85 mm Hg)
  • relevant comorbid conditions (diabetes mellitus, heart failure, active hepatic disease, digestive diseases with malabsorption, inflammation/anti-inflammatory therapy)
  • uremic complications (pericarditis, polyneuropathy)
  • feeding inability (anorexia, nausea)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

"Dr Carol Davila" Teaching Hospital of Nephrology

Bucharest, 010731, Romania

Location

Related Publications (2)

  • Mircescu G, Garneata L, Stancu SH, Capusa C. Effects of a supplemented hypoproteic diet in chronic kidney disease. J Ren Nutr. 2007 May;17(3):179-88. doi: 10.1053/j.jrn.2006.12.012.

  • Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 29;10(10):CD001892. doi: 10.1002/14651858.CD001892.pub5.

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

ketosterilDiet, Ketogenic

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diet, Carbohydrate-RestrictedDiet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Gabriel Mircescu, Prof

    Carol Davila University of Medicine and Pharmacy

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Nephrology, MD, PhD

Study Record Dates

First Submitted

January 7, 2014

First Posted

January 9, 2014

Study Start

March 1, 2008

Primary Completion

June 1, 2014

Study Completion

August 1, 2014

Last Updated

December 22, 2017

Record last verified: 2017-12

Locations